IQVIA Institute, a healthcare solutions company, evaluated FDA drug shortage information plus sales and volume data. On Nov. 15, IQVIA released a report showing that three-fourths of current drug shortages are older than a year.
The American Society of Health-System Pharmacists is also tracking 20 ongoing drug shortages that have lasted eight years.
Here are three key takeaways from the IQVIA report:
1. The trend of resolved shortages lacks a steady pattern, and most shortages ended during the second and third year of the COVID-19 pandemic.
2. Shortages are more common in the cheapest drugs. More than 50% cost less than $1, and 1.3% are priced more than $500 per unit.
3. Cancer drug shortages have been growing since 2020. As of mid-2023, cisplatin, methotrexate, capecitabine and carboplatin supply issues caused the most disruption in patient care. Despite this, the volume of shortages accounted for only 9% of the total oncology volume in June, and oncology volume is up 6% from June 2022.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.